Catalyst Pharmaceuticals, Inc.
Company & revenue
About Catalyst Pharmaceuticals, Inc.
Who they are
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS).
Detailed revenue, brand and relationship research has not yet been completed for CPRX.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
69
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
84
Strong
Financial Strength
89
Business Quality / Moat
87
Management
100
Growth Quality
47
Risk / Durability
84
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
82
Attractive
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
76/100
Building Historical Record
Model Score 76/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as mixed to moderately strong.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Balance-sheet / debt profile scores strongly
- •Valuation scores attractively
- •Recent buyback activity is present
- •M&A headline · Aug 9, 2026
- •M&A headline · Jul 16, 2026
- •M&A headline · Jul 10, 2026
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for CPRX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CPRX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is CPRX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is CPRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is CPRX's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
69
Opportunity Score
82
Market Cap
$3.85B
P/E Ratio
17.5
EPS
$1.80
52-Week High
$32.56
52-Week Low
$19.05
Beta
0.74
Intrinsic Value
$69.30
Analyst Target
$31.75
Shares Outstanding
127.3M
Total Revenue
$597.0M
Total Debt
$2.7M
Dividend
No current dividend
Liquidation Value / Share
$7.96
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Notices for CPRX
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Aug 9, 2026
California State Teachers Retirement System Acquires 30,717 Shares of Catalyst Pharmaceuticals, Inc. $CPRX — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldM&A headline · Jul 16, 2026
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
ReutersM&A headline · Jul 16, 2026
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Jul 10, 2026
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
MarketBeatCommunity Sentiment
0 active · 0 total callsNo personal call yet on CPRX.
What the Bulls Say
- +Product opportunity: Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic S.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
No strong bearish data point is currently available.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
69
Sep 17, 2026
Change
Unchanged
Current Score
69
Oct 1, 2026
Category Changes
CPRX score was unchanged.
Projected Score
Projected Score
73
Projected Change
+3.2%
Preliminary comparable-period financial changes suggest improvement of approximately 3.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$31.49
Intrinsic Value
$69.30
Difference
−$37.81
-54.6% vs IV
Margin of Safety
54.6%
Related Companies
BiotechnologyNews
Chuck Royce's Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts
California State Teachers Retirement System Acquires 30,717 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial